BioSpace News Archive

Stanford Health Care and Lucile Packard Children’s Hospital Stanford have been re-verified as a Level I adult and pediatric trauma center through May 2022 by the American College of Surgeons Committee on Trauma.

Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, announces the publication of two articles highlighting the potential of TG4001 and TG6002, two clinical-stage products, that are expected to generate new clinical data in H2 2019

Origin Agritech Ltd. (NASDAQ: SEED) (the “Company” or “Origin”), an agriculture technology and rural e-commerce company, today announced that the Company entered into a Cooperation Framework Agreement with Beijing Changping Technology Innodevelop Group (BC-TID) to form a new joint venture to focus on the commercialization of genetically modified (GM) corn seed technologies.

Concert Pharmaceuticals, Inc. announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on June 3, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 82,063 shares of Puma common stock to 15 new non-executive employees.

RVT-802, a one-time therapy, leverages Enzyvant’s T cell generation platform designed to treat profound immunodeficiencies

David P. King, current chairman, president and CEO of LabCorp, to become executive chairman of the board of directors effective Nov. 1, retiring Oct. 31 as president and CEO

Neurodegenerative Diseases: New Insights and Therapeutic Opportunities to advance discussion about therapies for Alzheimer’s disease among world’s leading researchers

Cytonus Therapeutics Inc., a biotechnology company developing new platforms for delivering biologics, announced that it will be presenting preclinical data for its Cargocyte™ technology platform program targeting difficult to treat Breast Cancer at the BIO International Convention meeting June 3-6 in Philadelphia, PA.

Soliton, Inc.,, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center, will conduct a webcast to discuss its recent announcements regarding its significant discovery of acoustic subcision and its 510 clearance for its acoustic shockwave RAP device.